- 05 November
-
Medsintez Plant participated in a key industry event, Product Innovation Fair in Medicine and Healthcare, which took place in Moscow on October 29–30. Viktor Fisenko, First Deputy Minister of Healthcare of Russia, attended the exhibition of domestic innovations in the field of drugs and medical products.
- 25 October
-
The 3d Scientific and Practical Conference The Ural Peaks. Respiratory Infections 2025 was held in Ekaterinburg on October 15–16 as part of the 4th International Forum Days of Virology 2025. The event organized by the Ministry of Health of the Sverdlovsk Region, the Smorodintsev Research Institute of Influenza, and the Ural State Medical University brought together over 1,100 participants in person and online from 36 cities across Russia.
- 24 October
-
In September 2025, the Russian Ministry of Health issued a registration certificate for a new dosage form of the broad-spectrum antiviral drug TRIAZAVIRIN® for the treatment of ARVI in school-age children—100 mg.
- 20 October
-
On October 10, 2025, a representative delegation visited the Medsintez Plant. Among the visitors, there were members of the State Duma of the Russian Federation, representatives of the Government and Legislative Assembly of the Sverdlovsk Region, the head of the Novouralsk Urban District, and leading regional experts in the field of medical science. The main purpose of the visit was to assess the enterprise's success in import-substituting drug production, become familiar with its brand-new products, and discuss development options of the pharmaceutical industry in the region.
- Home
- Cluster members
- Medica Group LLC
Medica Group LLC
Medica Group LLC is engaged in the localization of a joint Russian-Chinese project for the production of automatic microbiology analyzers on the territory of priority development in Novouralsk. The corresponding document was signed in the management company of the territory of advanced social and economic development (TASED) Atom- TOR. The project of localization of production in Russia was our response to the imposition of sanctions and threats of vital product lack. This project for the production of analyzers and culture vials gives us independence from foreign supplies.
Areas of company activities:
- Laboratory consumables;
- Modern solutions for microbiological laboratories;
- Medical equipment;
Clinical microbiology is an important link in the study of pathogenic features, pathogen diagnosis, rational use of antimicrobials and monitoring of nosocomial infection.
Sepsis is a fatal disease. About 30% of patients are misdiagnosed. This is due to the fact that current detection methods have low specificity and are slow. It takes days to get results, leading doctors to prescribe ineffective antibiotics, which in turn leads to the spread of antibiotic-resistant strains and increased deaths caused by blood infections. Every hour of delay in the use of effective antibiotics reduces survival by 7.6%. The introduction of innovative technologies in microbiological laboratories allows raising diagnostics to a new level, reducing the time for issuing results to 18-24 hours.
Automatic analyzers using advanced technology:
- YUNONA®LABSTAR model for testing the sterility of blood cultures and other biological fluids;
- Vials for blood cultures;
- YUNONA® HK model for identification of microorganisms and determination of sensitivity to antibiotics;
- Reagent kits for identification and sensitivity to antibiotics;
Automation of microbiological laboratories is an increase in the efficiency that directs the diagnosis, treatment and prevention of infectious diseases to obtain a quick and accurate diagnosis.
Medica Group of companies
Phone: +7 (343) 270-75-17
E-mail: medica.group@mail.ru
